For example, a large-scale clinical validation cohort is still required to further clarify our observed association of m6A regulators with PCa progression and their prognostic performance, in combination with the current PCa biomarkers (e.g., PSA, PCA3). Here, PCA3 is linked to posterior cortical atrophy.